Starting HIV Treatment May Reduce Serious Non-AIDS-Related Diseases in Newly Diagnosed, Study Finds
October 16, 2012
Starting HIV antiretroviral therapy may reduce the risk of serious non-AIDS-defining diseases in individuals recently diagnosed with HIV, according to a recent Spanish study published in the journal AIDS.
Although it is well known how modern HIV treatment has dramatically reduced AIDS-defining illnesses, it is less clear what impact antiretroviral therapy has on non-AIDS-defining illnesses (such as cardiovascular disease, cancers and psychiatric disorders), which have come to comprise an increasingly large proportion of the complications experienced by people living with HIV.
To explore this question, researchers from the Spanish AIDS Research Cohort (CoRIS) studied 5,185 treatment-naive patients, 86.5% of whom had been diagnosed in 2004 or later, and followed them until 2010. They found that the incidence rate of non-AIDS events (NAEs) was 28.93 per 1,000 person-years, while the incidence rate of AIDS-defining events was 25.23 per 1,000 person-years.
There were a total of 423 NAEs in 367 patients. The most common NAEs were psychiatric disorders, liver disease, cancers, kidney disease and cardiovascular disease. After adjusting for potential confounding factors, older age, a high viral load and a low CD4+ count were associated with the occurrence of NAEs, the investigators found.
However, starting treatment lowered the risk of NAEs, particularly psychiatric disorders and kidney disease. Aidsmap reported:
Depression requiring drug therapy accounted for 70% of all psychiatric events. Lung cancer (20%), non-Hogkin's lymphoma (14%), cancer of the head or neck (12%), liver cancer (9%) and anal cancer (9%) were the most common malignancies. The investigators note that most of these cancers were related to viral co-infections or lifestyle factors. They therefore recommend that "additional strategies should be adopted during the initial care to contribute to reducing mortality in recently diagnosed HIV-infected patients, including a more exhaustive intervention on HCV [hepatitis C virus], papillomavirus and smoking habits among others."
The median age of the participants was 36 years and 79% were men. About 68% of the cohort started treatment during the study period.
Warren Tong is the research editor for TheBody.com and TheBodyPRO.com.
Follow Warren on Twitter: @WarrenAtTheBody.
Copyright © 2012 Remedy Health Media, LLC. All rights reserved.
Stribild ("Quad") Recommended as Alternative First-Line HIV Treatment Regimen by U.S. Guidelines Panel
This article was provided by TheBodyPRO.com.
Add Your Comment:
(Please note: Your name and comment will be public, and may even show up in
Internet search results. Be careful when providing personal information! Before
adding your comment, please read TheBody.com's Comment Policy.)